Prescribing guide
Voyxact (sibeprenlimab)Dosing, infection screening, live vaccine timing and prior authorization criteria for IgA nephropathyFor prescribers and their offices treating IgA nephropathy: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS and no lab gate; assess for active infection, give any live vaccine more than 30 days before day 1, send the Prescription Start Form with the patient's signed consents to PANTHERx Rare, and the pharmacy contacts the patient before it ships.
Example PA threshold
Cigna IP0788 example: biopsy-confirmed primary IgAN, adult, proteinuria 0.5g a day or UPCR 0.5g/g or higher, 12 weeks of maximally tolerated ACEi or ARB, 3 months of supportive care, eGFR 30 or higher, nephrologist.
Monitoring
No scheduled lab in the label; infection assessment before starting and vigilance throughout, interruption to consider for serious infection, no live vaccines during treatment.
Support line
Otsuka Patient Services, 1-833-869-9228 (1-833-VOYXACT), Monday to Friday 8 AM to 8 PM Eastern, Start Form by fax 1-877-875-1264 or eScript to PANTHERx Rare, copay to $0 for commercial plans with an annual maximum up to $10,600, Bridge Program of up to three 28-day supplies.
Give your patient their plan
A one-page handout for starting Voyxact, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/voyxactBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Screen for active infection | The label says to assess for active infection before initiating. Patients with chronic or recurring infections may have an increased risk of serious infection. | FDA label |
| Live vaccines | Not recommended within 30 days prior to initiation or during treatment, as safety has not been established. No data on secondary transmission from persons receiving live vaccines, or on efficacy of immunizations given during treatment. | FDA label |
| Complete the Prescription Start Form | The form serves as the prescription and the Otsuka Patient Services enrollment. Attach the biopsy report, previous and current treatments with dates, UPCR or proteinuria, eGFR, other relevant labs and both sides of the insurance card. The patient signs the consent (section 7) and HIPAA authorization (section 8). The form lists ICD-10-CM codes N02.B1 to N02.B9 for IgAN. | Start Form |
| Write the prescription | The form prints it as Voyxact 400mg/2mL prefilled syringe, injected subcutaneously once every 4 weeks, 12 refills by default. A Bridge Program opt-in box is on the same page. | Start Form |
| Route to PANTHERx Rare | Fax 1-877-875-1264, or eScript to NPI 1750843314, PANTHERx Rare Specialty Pharmacy, Coraopolis, PA. | Start Form |
| Prior authorization | The prescriber prepares and submits the PA. Otsuka Patient Services can run a benefits investigation to find whether a PA is required and what the criteria are. Otsuka's checklist suggests considering a letter of medical necessity or formulary exception letter. | PA checklist |
| Bridge during a coverage delay | Commercially insured patients only, after primary coverage has been attempted. A 28-day supply; an additional 28-day refill requires that coverage is actively pursued, with a limit of three 28-day dispenses unless Otsuka grants more case by case. | Bridge terms |
| Field reimbursement and training | On opting in, the office and patient get a Field Reimbursement Manager for access and savings support and a Care Navigator for device training education. Otsuka Connect Representatives answer at 1-833-869-9228. Once a prescription is submitted, PANTHERx Rare contacts the patient directly and coordinates delivery. | Otsuka for offices |
| Uninsured or underinsured | The Otsuka Patient Assistance Foundation, a separate nonprofit, provides prescribed Otsuka medicines at no cost to eligible uninsured or underinsured patients; its supported-medications list references the Voyxact prescribing information. | Otsuka Patient Assistance Foundation |
| Patient training | The label says to train patients or caregivers on administration before use according to the Instructions for Use. Self-administration or caregiver administration is intended. | FDA label |
Prior authorization criteria and what to document
One public policy as the example: Cigna, July 15, 2026. Approval a year at a time, renewed if the prescriber reports a response such as lower urine protein and the eGFR is still 30 or higher. Cigna posts this version under a file name marked for individual and family plans, effective July 15, 2026. That revision lowered its urine protein-to-creatinine ratio bar from 0.8g/g to 0.5g/g. It cites the November 2025 prescribing information, which is the text still in the current label. Other plans set their own thresholds, and a full approval may change them. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Primary IgA nephropathy confirmed by biopsy, age 18 or older | Pathology report with date | Cigna policy |
| Proteinuria | 0.5g a day or more, or UPCR 0.5g/g or higher; the July 15, 2026 revision lowered the UPCR bar from 0.8g/g | Lab report with date and method | Cigna policy |
| RAS blockade | Maximum or maximally tolerated ACE inhibitor or ARB for at least 12 weeks before starting | Agent, dose, start date, and the reason if below the labeled maximum | Cigna policy |
| Supportive care | At least 3 months of optimized supportive care, per the prescriber: blood pressure management, lifestyle and cardiovascular risk modification | Blood pressure readings and the dated plan | Cigna policy |
| Kidney function | eGFR 30 or higher at initiation and renewal | Creatinine and eGFR with date | Cigna policy |
| Prescriber | Prescribed by or in consultation with a nephrologist | Specialty on the request, or the consult note | Cigna policy |
| Renewal | Response per the prescriber, such as a reduction in UPCR or proteinuria from baseline; 1-year approvals | Follow-up UPCR or proteinuria and eGFR with dates | Cigna policy |
| Other plans | Otsuka's checklist lists commonly requested items: biopsy, UPCR or proteinuria and eGFR, IgAN therapies in the past 12 months (ACEi or ARB, glucocorticoid, SGLT2 inhibitor, other IgAN-indicated drugs), and intolerance or contraindications for step therapy | Medication list with dates, and any letter of medical necessity | PA checklist |
Voyxact dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 | 400mg SC once every 4 weeks, one single-dose prefilled syringe (400mg/2mL, 200mg/mL), front of the thigh or abdomen avoiding 2 inches around the navel; back of the upper arm if a caregiver injects. Rotate sites. No titration or loading dose. Each carton holds 1 syringe (NDC 59148-400-75), so each fill is one dose. | FDA label |
| Before each dose | Out of the refrigerator 15 to 30 minutes to reach room temperature up to 77°F (25°C); no other warming. Solution clear to opalescent, colorless to yellow; do not use if cloudy, discolored or particulate. | FDA label |
| Technique | Pinch the skin and insert the whole 27 gauge, ½ inch needle at 45 degrees; push the plunger fully; the needle guard covers the needle on release. Do not remove air bubbles. | FDA label |
| Missed dose | Give as soon as possible, then resume dosing every 4 weeks thereafter. | FDA label |
| Storage | 2 to 8°C (36 to 46°F) in the original carton; once at room temperature, never refrigerated again; do not use after 7 days or more at room temperature. Do not freeze, shake or expose to heat or direct sunlight. | FDA label |
| Pharmacokinetics | Steady state by 20 weeks; median Tmax 8 days; bioavailability about 92% with no difference by abdomen, thigh or arm; mean terminal half-life 9.3 days after a single dose; clearance 206mL/day. No clinically relevant differences by sex, age, weight, race or eGFR 30 to 89. | FDA label |
| Special populations | No dedicated renal or hepatic impairment studies. Safety and effectiveness not established in children. Too few patients 65 or older to tell whether response differs; no clinically meaningful PK difference with age. | FDA label |
Monitoring the Voyxact label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before day 1 | Active infection; live vaccine timing | Assess for active infection; no live vaccines within 30 days before initiation | FDA label |
| Any time | Infection: fever, chills, fatigue, cough, flu-like symptoms, aches, warm, red or painful skin | Consider interrupting Voyxact until a serious infection is controlled; infections 49% against 45% on placebo in VISIONARY, upper respiratory infection 15% against 14% | FDA label |
| Over 2 years | Serious infections | Otsuka reported on October 22, 2026 that serious infections were 1.9% on Voyxact and 4.0% on placebo through 2 years; company data, not yet in the label | Otsuka, Oct 2026 |
| Any time | Hypersensitivity | Counsel patients to discontinue and seek immediate care; serious hypersensitivity to sibeprenlimab-szsi or excipients is the only contraindication | FDA label |
| Any time | Injection site reactions | 24% against 23%; erythema 13% against 12%; most adverse reactions mild or moderate and resolved without interruption or discontinuation | FDA label |
| Pharmacodynamics | Serum APRIL, Gd-IgA1, IgA, IgG and IgM | APRIL suppression above 90% by week 4. By week 48 mean levels fell 67% (Gd-IgA1), 69% (IgA), 35% (IgG) and 75% (IgM) from baseline. The label sets no immunoglobulin monitoring schedule | FDA label |
Voyxact drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| No section 7 | The label has no drug interactions section; sibeprenlimab-szsi is an IgG2 monoclonal antibody expected to be degraded by catabolic pathways like endogenous IgG | FDA label |
| Immunosuppressants | Limited clinical data with systemic immunosuppressants; consider the potential for increased immunosuppression when coadministering or when starting Voyxact before or after immunosuppressive therapy. VISIONARY excluded patients on systemic immunosuppressants in the 16 weeks before screening | FDA label |
| Vaccines | Live vaccines not recommended within 30 days before initiation or during treatment; responses to other vaccines may be reduced | FDA label |
| Pregnancy and lactation | No human data; IgG transfer across the placenta rises through the third trimester, so infants exposed in utero may carry the drug; report exposure to 1-833-869-9228; no data on milk transfer | FDA label |
| Postmarketing | The approval letter requires a confirmatory trial (final report due April 2027), a pediatric study in ages 2 to 17, a lactation study and a worldwide pregnancy exposure study | FDA letter |
Why a first fill stalls, and the fix
- The prescription went to a retail pharmacyOtsuka says Voyxact is only available from a specialty pharmacy, PANTHERx Rare. The office resends the Start Form by fax to 1-877-875-1264 or e-prescribes to PANTHERx Rare. This is a routing problem for the office to fix, not a denial.
- The pharmacy has not reached youOtsuka says PANTHERx Rare will call you to set up your shipments of Voyxact. A missed call from the pharmacy can hold up the first carton. Call 833-869-9228, Monday to Friday, 8 AM to 8 PM Eastern, or use the PANTHERx Rare app.
- The Start Form is missing your signature or recordsThe form asks for the biopsy, current and past treatments with dates, urine protein, kidney function and a copy of the insurance card. Your own signature goes on the consent and HIPAA pages. Ask the office whether every page went in with the form.
- Prior authorization pending or deniedCigna, for example, asks for the biopsy, a protein level, 12 weeks on an ACE inhibitor or ARB, and a nephrologist. The full list is below, and the nephrologist's records usually answer it.
- A commercial plan is slow to decideThe Bridge Program may supply Voyxact at no cost after coverage has been attempted and is delayed. It allows up to three 28-day supplies while you actively pursue coverage.
- A copay you cannot payCommercial insurance may qualify for the Voyxact Copay Program, as little as $0 up to a yearly maximum of up to $10,600. Medicare Part D, Medicaid, Medigap, VA, DoD and TRICARE are excluded by its terms. Our help paying page lists the charity funds that are open.
Otsuka Patient Services
- An Otsuka Care Navigator who gives education about IgA nephropathy and Voyxact and help with the prefilled syringe, without replacing your nephrologist
- The Voyxact Copay Program for commercial insurance, as little as $0, with no copay card needed
- Copay benefits that may apply to copays, coinsurance and pharmacy deductibles, with a maximum yearly benefit and other limits
- The Bridge Program, temporary access for commercially insured patients facing insurance coverage challenges, so they may start while coverage is being determined
- Calls from Otsuka Patient Services to help you get started, which you can change at any time at 833-869-9228
Questions prescribers' offices ask about Voyxact
What is the Voyxact dose?
400mg injected subcutaneously once every 4 weeks from a single-dose prefilled syringe, per the November 2025 label (DailyMed version dated March 17, 2026). There is no titration or loading dose; a missed dose is given as soon as possible and dosing resumes every 4 weeks from it.
Are vaccines required before Voyxact?
No specific series is required by the November 2025 label. It says live vaccines are not recommended within 30 days before initiation or during treatment, that Voyxact may interfere with vaccine responses, and that no data exist on the efficacy of immunizations given during treatment.
Is there a REMS for Voyxact?
No. The FDA's November 19, 2025 REMS review concluded a REMS was not necessary, the November 25, 2025 approval letter imposes none, and the label has no boxed warning. Dispensing runs through PANTHERx Rare, which Otsuka names as the specialty pharmacy.
What monitoring does the Voyxact label require?
None on a fixed schedule in the November 2025 label. It asks prescribers to assess for active infection before starting, monitor for signs and symptoms of infection during treatment, and consider interrupting Voyxact until a serious infection is controlled.
What do insurers ask for to approve Voyxact?
Cigna policy IP0788 shown on this page, effective July 15, 2026, asks for biopsy-confirmed primary IgAN in an adult, proteinuria of 0.5g a day or UPCR of 0.5g/g or more, 12 weeks of maximally tolerated ACEi or ARB, 3 months of supportive care, eGFR of 30 or higher and a nephrologist. It approves 1 year at a time.
Free email alert
Get an email when the Voyxact label changes
One email the day the FDA revises the Voyxact prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Voyxact only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- VOYXACT (sibeprenlimab-szsi) injection, prescribing information, Patient Information and Instructions for Use, revised November 2025, Otsuka, via DailyMed and openFDA, 2026-03-17.
- BLA 761434 accelerated approval letter, Voyxact (sibeprenlimab-szsi), FDA, 2025-11-25.
- BLA 761434 Risk Assessment and Risk Mitigation Review, Evaluation of Need for a REMS, FDA, 2025-11-19.
- Otsuka Presents Landmark Final Phase 3 VISIONARY Results at ASN Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilized Kidney Function and Reduced Risk of Disease Progression and Kidney Failure, Redefining Treatment Paradigm in IgA Nephropathy, Otsuka, 2026-10-22.
- Patient Support | VOYXACT® (sibeprenlimab-szsi), Otsuka, 2026-11-09.
- VOYXACT Copay Program Terms and Conditions, Otsuka, 2026-11-09.
- VOYXACT Bridge Program Terms and Conditions, Otsuka, 2026-11-09.
- Resources & FAQs | VOYXACT® (sibeprenlimab-szsi), Otsuka, 2026-11-09.
- Support | VOYXACT® (sibeprenlimab-szsi) HCP, Otsuka, 2026-11-09.
- VOYXACT Prescription Start Form (21US26EBP0020, May 2026), Otsuka, 2026-11-09.
- VOYXACT Prior Authorization Checklist (21US25EBP0022, September 2025), Otsuka, 2026-11-09.
- Drug Coverage Policy IP0788, Nephrology, Voyxact, Cigna, 2026-07-15.
- Otsuka Patient Assistance Foundation | No-Cost Treatment Support & Coverage, Otsuka Patient Assistance Foundation, 2026-11-09.
A reference drawn from the March 17, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 9, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.